Threshold Pharmaceuticals Inc. (NASDAQ:THLD)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a research report issued on Monday.
Separately, S&P Equity Research decreased their price target on shares of Threshold Pharmaceuticals from $0.67 to $0.52 in a research note on Friday, September 30th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $7.26.
Shares of Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.5531 on Monday. The stock has a 50 day moving average of $1.05 and a 200 day moving average of $0.62. Threshold Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $4.44. The company has a market cap of $39.55 million, a price-to-earnings ratio of 0.9343 and a beta of 3.98.
Threshold Pharmaceuticals (NASDAQ:THLD) last issued its quarterly earnings results on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). On average, equities research analysts expect that Threshold Pharmaceuticals will post ($0.38) EPS for the current year.
A number of hedge funds have recently made changes to their positions in THLD. Oxford Asset Management increased its stake in shares of Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares during the period. Paloma Partners Management Co purchased a new stake in shares of Threshold Pharmaceuticals during the second quarter valued at approximately $152,000. Renaissance Technologies LLC increased its stake in shares of Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 363,100 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 500,000 shares during the period. Finally, Deerfield Management Co. purchased a new stake in shares of Threshold Pharmaceuticals during the second quarter valued at approximately $1,641,000. 28.22% of the stock is currently owned by institutional investors.
Threshold Pharmaceuticals Company Profile
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.